Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coltuximab ravtansine

Drug Profile

Coltuximab ravtansine

Alternative Names: Anti-CD19-DM4 immunoconjugate SAR3419; huB4-DM4; Maytansin-loaded anti-CD19 mAb; SAR-3419

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action CD19 antigen inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Diffuse large B cell lymphoma

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Discontinued Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Sep 2016 Coltuximab ravtansine is available for licensing as of 30 Sep 2016. http://www.immunogen.com/
  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 27 Jun 2015 Coltuximab ravtansine is still in phase II trials for Diffuse large B-cell lymphoma in Belgium, Czech Republic, Italy, Poland, Spain and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top